Clinical Trials Logo

Primary Open Angle Glaucoma clinical trials

View clinical trials related to Primary Open Angle Glaucoma.

Filter by:

NCT ID: NCT02792803 Recruiting - Ocular Hypertension Clinical Trials

A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

Start date: September 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients with primary open angle glaucoma. The study will also aim to prove the tolerability of Xalatan in terms of ocular hyperemia will be equivalent to its generic counterparts.

NCT ID: NCT02623738 Completed - Ocular Hypertension Clinical Trials

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Start date: December 6, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with DE-117 ophthalmic solution is non-inferior to latanoprost ophthalmic solution 0.005%.

NCT ID: NCT02617459 Completed - Ocular Hypertension Clinical Trials

Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension

Start date: January 4, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.

NCT ID: NCT02544646 Completed - Glaucoma Clinical Trials

Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG

Start date: October 13, 2011
Phase: N/A
Study type: Interventional

It has been hypothesized that the biomechanical properties of the optic nerve head and/or sclera play a role in the development of glaucoma. One approach of gaining insight into the biomechanical properties of the eye by the means of clinical studies is based on the Friedenwald equation, representing a pressure-volume relationship. This equation represents the so called ocular rigidity, which expresses the elasticity of the globe. In order to be able to solve the equation, measurements of fundus pulsation amplitude (FPA) with laser interferometry and dynamic contour tonometric assessment of the pulse amplitude (PA) have to be performed. In addition choroidal thickness will be assessed with OCT before and after trabeculectomy, since results in choroidal thickness measurements in patients with glaucoma are controversial. The focus of this study lies on the changes of ocular rigidity and choroidal thickness after surgical trabeculectomy in patients with primary open angle glaucoma (POAG) or pseudoexfoliation glaucoma (PEX).

NCT ID: NCT02539745 Completed - Clinical trials for Vitamin D Deficiency

Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma

Start date: July 2013
Phase: N/A
Study type: Observational

This study investigated whether vitamin D receptor gene polymorphism is altered in primary open-angle glaucoma subjects carrying the risk allele and vitamin D deficiency is an important factor in the development of glaucoma. Primary open-angle glaucoma patients and age-matched people in the Han population were enrolled. Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay. Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.

NCT ID: NCT02537015 Completed - Ocular Hypertension Clinical Trials

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

OLE2
Start date: August 10, 2015
Phase: Phase 2
Study type: Interventional

This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004. All the participants received Bimatoprost Ocular Insert and wore it for approximately 3 months (12 weeks), then had that Insert removed and a new Insert placed for another 26 weeks (approximately 6 months).

NCT ID: NCT02406833 Completed - Clinical trials for Primary Open Angle Glaucoma

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

Start date: April 2015
Phase: Phase 1
Study type: Interventional

This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2, to glaucoma filtration surgery (trabeculectomy). The treatment aims at improving the surgery outcome by prevention of excessive scarring and trabecular meshwork transformation.

NCT ID: NCT02358369 Completed - Ocular Hypertension Clinical Trials

Dose-Ranging Study of the Bimatoprost Ocular Insert

Start date: January 19, 2015
Phase: Phase 2
Study type: Interventional

The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension. This study evaluated the safety and efficacy of two different doses of the Bimatoprost Ocular Insert, compared to an active control arm with timolol ophthalmic solution (0.5%).

NCT ID: NCT02355990 Completed - Clinical trials for Primary Open Angle Glaucoma

Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study

Start date: February 1, 2015
Phase: N/A
Study type: Interventional

The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.

NCT ID: NCT02330978 Completed - Clinical trials for Retinal Degeneration

Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.

Start date: January 2014
Phase: Phase 1
Study type: Interventional

Bone marrow-derived mesenchymal stem cells (MSC) therapy is a promising treatment for several degenerative diseases, including retinopathies and glaucoma, however no previous safety study involving humans has been conducted. The objective of this study is to evaluate effects of autologous bone marrow-derived MSC transplantation in the worst eye of 10 patients with legal bilateral blindness due to glaucoma. Primary outcome are types and severity of adverse effects. Secondary outcomes are changes in visual field, visual acuity, optical coherence tomography, and retinal ganglion cells function.